• OPEN AN ACCOUNT
Indian Indices
Nifty
25,461.00 55.70
(0.22%)
Sensex
83,432.89 193.42
( 0.23%)
Bank Nifty
57,031.90 239.95
( 0.42%)
Nifty IT
39,166.55 312.25
( 0.80%)
Global Indices
Nasdaq
44,849.54 344.11
(0.77%)
Dow Jones
6,300.35 51.93
(0.83%)
Hang Seng
39,792.23 6.33
(0.02%)
Nikkei 225
8,822.91 -0.29
(0.00%)
Forex
USD-INR
85.44 -0.20
(-0.23%)
EUR-INR
100.61 -0.32
(-0.32%)
GBP-INR
116.59 -0.52
(-0.45%)
JPY-INR
0.59 0.00
(-0.64%)

EQUITY - MARKET SCREENER

Latteys Industries Ltd
Industry :  Pumps
BSE Code
ISIN Demat
Book Value()
535085
INE262Z01023
3.5288067
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LATTEYS
80.42
143.34
EPS(TTM)
Face Value()
Div & Yield %
0.31
2
0
 

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel
Jul 01,2025
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%. Loteprednol Etabonate Ophthalmic Gel, 0.38% is bioequivalent to Lotemax® SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Pithampur facility in India.

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax® SM) had an estimated annual sale of USD 29 million in the U.S. (IQVIA MAT May 2025).